Chemical constituents from marine medicinal brown alga-derived Scytalidium lignicola SC228

Abstract

In this study, a marine medicinal brown alga Sargassum cristaefolium-derived fungal strain Scytalidium lignicola SC228 has been isolated and identified. Column chromatography of the extracts from liquid-fermented products of the fungal strain was carried out, and led to the purification of eight compounds. Their structures were characterized by spectroscopic analysis, and the absolute configurations were further established by single X-ray diffraction analysis and modified Mosher's method as four previously undescribed compounds, namely scytabenzofurans A–C (1–3), and (3S,4S)-5-chloro-3,4-dihydro-4,6,8-trihydroxy-3-methyl-1H-2-benzopyran-1-one (4), along with four known compounds 5–8. All the isolates were subjected to anti-inflammatory and anti-angiogenic assays. Compounds 1–4, 7, and 8 showed moderate nitric oxide production inhibitory activities in lipopolysaccharide-activated BV-2 microglial cells with IC₅₀ in the range of 19.6 ± 0.1 to 49.0 ± 1.2 μM in comparison with that of curcumin (IC₅₀ = 2.7 ± 0.3 μM). Compounds 5–7 exhibited moderate to potent inhibitory effects on EPCs growth with IC₅₀ in the range of 0.5 ± 0.1 to 42.7 ± 0.9 μM as compared to sorafenib (IC₅₀ = 5.50 ± 1.50 μM).